# US 12,599,591 B2 · Vemurafenib and salts thereof for use in the treatment of enteroviral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,599,591 B2
- Document ID: US12599591B2
- Status: Granted
- Kind: B2
- Application number: 17/281,650
- Filed: 2019-10-03
- Published: 2021-08-12
- Granted: 2026-04-14
- Earliest claimed: 2018-10-03
- Assignees: JyväSkyläN Yliopisto
- Applicants: Jyväskylän yliopisto
- Inventors: Varpu Marjomäki; Mira Laajala; Mari Martikainen
- Web page: https://patentgrep.com/patent/US12599591B2

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61P 31/16: for influenza or rhinoviruses
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides N-(3-(5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonamide known as vemurafenib, and pharmaceutical salts thereof for use in the treatment of enteroviral diseases.

## Claims

### Claim 1

A method for treating, alleviating, or reducing an enteroviral infection caused by an enterovirus comprising administering a pharmaceutical product comprising vemurafenib or a pharmaceutically acceptable salt thereof to a subject suffering from said enteroviral infection, wherein the enterovirus is selected from the group consisting of coxsackieviruses B and polioviruses.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said product comprises vemurafenib in its amorphous form.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said product comprises hydroxypropyl methylcellulose acetate succinate (HPMC-AS).

### Claim 4 (depends on 1)

The method according to claim 1, wherein said product comprises vemurafenib hydrochloride.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said enteroviral infection causes poliomyelitis, polio-like syndrome, pericarditis, myocarditis, or type 1 diabetes.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said product comprises at least one pharmaceutically acceptable buffer, carrier, excipient, preservative or adjuvant.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the product is a tablet and the tablet comprises colloidal anhydrous silica, croscarmellose sodium, hydroxypropylcellulose, and magnesium stearate as excipients.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said product is formulated for sustained-release, delayed-release, or timed-release, or said product comprises a blend of sustained-release and immediate-release formulations.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said enteroviral infection is caused by a coxsackie B virus.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said enteroviral infection causes pericarditis, myocarditis or type 1 diabetes.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said enteroviral infection is caused by coxsackie B virus 4 (CVB4).

### Claim 12 (depends on 1)

The method according to claim 1, wherein said enteroviral infection is caused by a poliovirus.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said enteroviral infection causes poliomyelitis or a polio-like syndrome.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said enteroviral infection is caused by poliovirus 3.